Osteonectin / SPARC Protein & Antibody

Secreted protein, acidic, cysteine-rich (Osteonectin)

Osteonectin / SPARC Products

Osteonectin / SPARC Protein, Recombinant

Molecule	Species	Description //For Detailed Info. and Price------CLICK!	Cat. No
Osteonectin/SPARC	Human	Osteonectin/SPARC Protein, Recombinant	10929-H08H
Osteonectin/SPARC	Mouse	Osteonectin/SPARC Protein, Recombinant	50494-M08H

Osteonectin / SPARC Antibody

Molecule	Application	Description //For Detailed Info. and Price------CLICK!	Cat. No
Human Osteonectin/SPARC	ELISA	Osteonectin/SPARC Antibody, Rabbit MAb	10929-R001
Human Osteonectin/SPARC	WB, ELISA	Rabbit Polyclonal Antibody	10929-RP01
Human Osteonectin/SPARC	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	10929-RP02
Mouse Osteonectin/SPARC	WB, ELISA	Osteonectin / SPARC Antibody	50494-RP01
Mouse Osteonectin/SPARC	WB, ELISA	Osteonectin / SPARC Antibody (Antigen Affinity Purified)	50494-RP02

Osteonectin / SPARC cDNA Clone

Molecule	Species	Description //For Detailed Info. and Price------CLICK!	Cat. No
Osteonectin/SPARC	Human	Homo sapiens Osteonectin/SPARC cDNA Clone(NM_003118.2)	HG10929-M
Osteonectin/SPARC	Mouse	Mus musculus Osteonectin/SPARC cDNA Clone	MG50494-M

Osteonectin / SPARC Related Areas

Stem Cell>>Mesenchymal Stem Cell (MSC)>>Osteoblast & Osteoclast Marker>>Osteonectin/SPARC

Stem Cell>>Embryonic Stem Cell (ESC)>>Embryonic Stem Cell Marker>>Osteonectin/SPARC

Cancer>>Angiogenesis>>ECM Molecules in Angiogenesis>>Osteonectin/SPARC

Immunology>>Adhesion Molecule>>Extracellular Matrix Molecule>>Extracellular Matrix Protein>>Osteonectin/SPARC

Osteonectin / SPARC Alternative Names

Osteonectin, SPARC, ON, cysteine-rich protein [Homo sapiens]

Osteonectin, Sparc, RP23-465I4.1, AA517111, BM-40 [Mus musculus]

Osteonectin / SPARC Background

Secreted protein acidic and rich in cysteine (SPARC), also known as Osteonectin (ON), is a member of the SPARC family. SPARC consists of three domains: a EF-hand domain, a follistatin-like domain and a Kazal-like domain, and each of which has independent activity and unique properties. The activity of SPARC is context- and cell-type-dependent, which is highlighted by the fact that SPARC has shown seemingly contradictory effects on tumor progression in both clinical correlative studies and in animal models. The location of SPARC in the nuclear matrix of certain proliferating cells, but only in the cytosol of postmitotic neurons, indicates potential functions of SPARC as a nuclear protein, which might be involved in the regulation of cell cycle progression and mitosis. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Notably, SPARC is linked to human obesity. SPARC derived from adipose tissue is associated with insulin resistance and secretion of SPARC by adipose tissue is increased by insulin and the adipokine leptin.

Osteonectin / SPARC Related Studies

1. Yan Q, et al. (1999) SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 47(12): 1495-506.
2. Brekken RA, et al. (2000) SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19(7): 569-80.
3. Tai IT, et al. (2008) SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 11(6): 231-46.
4. Podhajcer OL, et al. (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 27(3): 523-37.
5. Kos K, et al. (2010) SPARC: a key player in the pathologies associated with obesity and diabetes. Nat Rev Endocrinol. 6(4): 225-35.